Richter Gedeon Vegyeszeti Gyar Nyilvanosan Muko Rt 2024 IR
The report highlights Gedeon Richter Plc.'s record-high financial results for 2024, with pharmaceutical revenues growing by 13% to HUF 845 billion and net income increasing by 51% to HUF 239 billion. The company achieved major operational milestones, including becoming the largest oral contraceptive player in Europe and expanding its biotechnology CDMO capacity. Key strategic acquisitions were completed, including assets from Mithra Pharmaceuticals and BCI Pharma, which established a new original research hub in Belgium. Additionally, the company reduced its group-level Scope 1, 2, and 3 greenhouse gas emissions by 4% while aligning its carbon footprint targets with the Science Based Targets initiative.
Company: Richter Gedeon Vegyeszeti Gyar Nyilvanosan Muko Rt
Sector: Health Care
Country: Hungary
Year: 2024
Type: IR
Pages: 291
Richter Gedeon Vegyeszeti Gyar Nyilvanosan Muko Rt
Consolidated Annual Report
The report highlights Gedeon Richter Plc.'s record-high financial results for 2024, with pharmaceutical revenues growing by 13% to HUF 845 billion and net income increasing by 51% to HUF 239 billion. The company achieved major operational milestones, including becoming the largest oral contraceptive player in Europe and expanding its biotechnology CDMO capacity. Key strategic acquisitions were completed, including assets from Mithra Pharmaceuticals and BCI Pharma, which established a new original research hub in Belgium. Additionally, the company reduced its group-level Scope 1, 2, and 3 greenhouse gas emissions by 4% while aligning its carbon footprint targets with the Science Based Targets initiative.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees